4 April 2017 - The aim of this study was to conduct an analysis on the regulation and application of managed entry agreements for oncology drugs across different European countries.

Literature search and document analysis were performed between September 2015 and June 2016 to collect information on the regulatory framework and practice of managed entry agreements (MEAs) in Belgium, The Netherlands, Scotland, England and Wales, Sweden, Italy, Czech Republic and France. An overview of the content and typology of MEA applied for oncology drugs between 2008 and 2015 was generated based on publicly available sources and contributions by national health authorities. Semi-structured interviews were conducted with representatives of national health authorities involved in the management or negotiation of MEA.

Read Frontiers in Pharmacology article